Aims: In patients at high risk of bleeding who undergo PCI, the Biolimus A9 polymer-free drug-coated stent (DCS) has superior efficacy and safety compared to a bare metal stent (BMS). We estimated the costeffectiveness of DCS vs. BMS.
Introduction
The choice of drug-coated stents vs. bare metal stents for patients undergoing percutaneous revascularisation is based upon medical criteria but also has economic implications due to the large number of patients receiving stents worldwide. In populations that are not at increased risk of bleeding, drug-eluting stents were found to be cost-effective compared to bare metal stents in patients at high risk of cardiac events 1 . At least 15% of patients who undergo percutaneous coronary intervention (PCI) are at increased risk of bleeding 2, 3 , at a cost of US $4,000-14,000 per episode 4 . Due to their relative or absolute contraindication to prolonged dual antiplatelet therapy (DAPT), these patients at high risk of bleeding are often treated with bare metal stents followed by one month of DAPT only 5, 6 , which is associated with a higher risk of restenosis and reintervention than that observed with the use of a drug-eluting stent 7 . LEADERS FREE was a double-blind multicentre trial including nearly 2,500 patients at high risk of bleeding comparing BioFreedom™ (Biosensors Europe, Morges, Switzerland), a new Biolimus A9 polymer-free drug-coated stent, to a bare metal stent. The Biolimus A9 drug-coated stent demonstrated superiority at one year in terms of both safety (composite endpoint of death, MI and stent thrombosis of 9.4% vs. 12.9%, p<0.005) and efficacy (clinically indicated target lesion revascularisation of 5.1% vs. 9.8%, p<0.001), all patients being treated with one month only of DAPT followed by single antiplatelet treatment 8 .
We performed a prospective health economic evaluation alongside the LEADERS FREE trial to understand the cost-effectiveness of these alternative stenting strategies.
Methods

STUDY DESIGN AND ORGANISATION
The design and results of the LEADERS FREE trial have been described previously 8 . Between December 2012 and May 2014, 2,466 patients at increased bleeding risk underwent randomisation to treatment with a Biolimus A9 (BA9) coated stent or a bare metal stent. The prospective economic evaluation was concurrent with the randomised trial, in accordance with the CHEERS guidelines 9 . The perspective chosen was that of the healthcare system; resources and quality of life were collected prospectively alongside the clinical trial. Study participants lost to follow-up were included in the analysis. LEADERS FREE was conducted at 68 sites in 20 countries on four continents. The cost weights used in the economic analysis were obtained from countries where the number of patients included allowed precise estimates of country-specific values (England, France, Germany, Italy, Scotland and Spain). We analysed the overall trial population using cost weights from each of the six countries mentioned [10] [11] [12] . LEADERS FREE ClinicalTrials.gov number: NCT01623180.
EFFECTIVENESS
The economic evaluation used components of the safety and efficacy endpoints (cardiac death, target vessel myocardial infarction, target vessel stent thrombosis and target lesion revascularisation) and quality-adjusted life-years (QALY). The use of clinical endpoints as effectiveness criteria is standard in economic evaluations of cardiac interventions 1, 11 , and the use of QALY is recommended by the CHEERS guidelines 9 . Because the clinical study found homogeneity of safety and efficacy between study locations, we pooled the one-year clinical results from all countries 8 .
ESTIMATION OF RESOURCE UTILISATION
All costs were assessed from the perspective of the healthcare system. The time horizon was one year. We verified practice heterogeneity between countries to ensure that medical resource utilisation could be pooled for the cost analysis.
Post-procedural days for each initial hospitalisation were recorded prospectively. The follow-up cardiovascular hospitalisations were included in the economic evaluation if at least one concurrent adjudicated cardiac clinical endpoint was recorded between the day before the admission date and the discharge date.
Outpatient resources (doctor visits, medications, non-invasive exams, etc.) were not included in the cost calculations as all patients were prescribed identical scheduled follow-up in both arms and we assumed that all significant events would result in a hospital admission. For the same reason, hospitalisations for bleeding events were not counted either, as the antiplatelet therapy regimen was identical in the two groups, and bleeding events were not different between the two groups.
ESTIMATION OF UNIT COSTS
Total hospital costs were calculated as daily hospital costs multiplied by the length of stay. Either PCI or cardiac-related daily costs were applied to re-hospitalisations depending on whether a PCI procedure was performed. Costs were reported with the hospital costs of each country. Costs were reported in euros; British pounds were converted to euros using a purchasing power parity of 1.34. As stent prices vary per country, we calculated an average price mark-up of €300 for a drug-coated stent over a bare metal stent. Similar stent prices were used in all countries, as in the SYNTAX trial 13 .
QUALITY OF LIFE
The main outcome was expressed as QALY assessed directly from patients at baseline and at one year with the EuroQOL EQ-5D-5L questionnaire 14 health status instrument, and converted to country-specific utility weights for each studied country (UK weights were selected for both England and Scotland). The initial weight reflecting the quality of life at the time of the PCI was attributed to the entire month following the initial procedure. The trial did not record the EuroQOL at regular intervals during the follow-up period. We assumed that each adverse event would be associated with a utility decrement and therefore attributed the initial weight to the month following each adverse event, while the final utility weight at one year was attributed to the remaining time, except when the final utility weight was worse than at inclusion: in that case the initial weight was not used to decrement utility. Missing follow-up utilities because of premature death were imputed through linear regression prediction to the time of death. QALY were calculated for each patient as the time-weighted average of utility values.
COST-EFFECTIVENESS
A cost-effectiveness analysis was conducted to estimate incremental costs per incremental QALY for the primary analysis and clinical endpoints for the secondary analysis 15 . Costs and QALY were not discounted due to the short time horizon.
UNCERTAINTY ANALYSIS
Bootstrapping (10,000 replicates) was used to estimate uncertainty in the joint distribution of costs, clinical endpoints and QALY for each treatment group. Results were presented on the cost-effectiveness plane and as a cost-effectiveness acceptability curve 16 .
STATISTICAL ANALYSIS
Categorical data are reported as frequencies, and continuous data are reported as mean±SD. Discrete variables were compared by use of Fisher's exact tests. Continuous variables (including costs) were compared using bootstrap hypothesis testing in order to avoid relying on normality assumptions 17 . Count data were compared with a Poisson model. All analyses were performed with R version 3.2.3 18 , and results were plotted with the ggplot2 R package 19 .
Results
PATIENT POPULATION
A total of 2,466 patients underwent randomisation (1,239 were assigned to the drug-coated stent and 1,227 were assigned to the bare metal stent) from December 2012 to May 2014. Of the 2,432 patients who underwent PCI, 2,385 (98.1%) were followed until death or 390 days.
EFFECTIVENESS
In accordance with the clinical results 8 , the number of clinical safety and efficacy endpoints per patient was lower in the drugcoated stent group with an average reduction of 0.095 events per patient (0.152 vs. 0.237; p<0.001) ( Table 1) .
UTILITY WEIGHTS AND QALY
QALY of the one-year follow-up were non-significantly higher in the drug-coated stent group, ranging from 0.671 to 0.790 across countries vs. 0.662 to 0.713 for the bare metal stent group (difference from 0.008 to 0.010). Utilities and cumulative QALY are presented in Table 1 .
TREATMENT COSTS
Resource use for the initial revascularisation procedures is summarised in Table 2 . The average number of stents, angioplasty balloons and guiding wires was identical in both groups. Total procedural hospitalisation costs were similar between groups (non-significant cost differences in favour of the drug-coated stent group: England -160 €, France -202 €, Germany -148 €, Italy -226 €, Scotland -139 €, Spain -295 €) ( Table 3 ). The total stent cost was higher for the drug-coated group based on an average of 1.8 stents per patient (cost difference: €557) ( Table 3) .
The difference in rates of cardiac death, target vessel myocardial infarction, target vessel stent thrombosis, target lesion revascularisation and length of stay was consistently in favour of the drug-coated stent group (Table 2) , resulting in higher post-procedural hospital costs in the bare metal stent group in all countries (cost differences in favour of the drug-coated stent group: England -985 €, France -695 €, Germany -591 €, Italy -1,079 €, Scotland -856 €, Spain -1,411 €) ( Table 3 ). The total one-year costs, including stent costs, were lower in the drugcoated stent group (cost differences: England -588 €, France -339 €, Germany -181 €, Italy -748 €, Scotland -437 €, Spain -1,149 €) ( Table 3 ). None of these differences reached statistical significance.
COST-EFFECTIVENESS AND SENSITIVITY ANALYSES
The probability that drug-coated stents dominated bare metal stents (i.e., were both more effective and less costly) depended on the country studied and on the outcome chosen (QALY or clinical endpoints), but remained above 50% in all situations. In the QALY analysis, drug-coated stent dominance was found in: England 65%, France 57%, Germany 52%, Italy 69%, Scotland 62%, and Spain 72%. In the clinical events analysis, drug-coated stent dominance was found in: England 85%, France 75%, Germany 67%, Italy 87%, Scotland 80%, and Spain 91% (Figure 1) .
If stakeholders were ready to pay €50,000 per QALY, the probability of being cost-effective was 70-75% for all countries. At a threshold of €10,000 per clinical event averted, drug-coated stents had a 98% probability of being cost-effective in all countries (Figure 2) .
We found that the initial admission length of stay was slightly higher for the bare metal stent group, resulting in higher hospitalisation costs for the index procedure. Since the investigators were blinded, there was no obvious clinical explanation for this non-significant difference except random fluctuation. To ensure strict comparison of effects and costs, we set the difference in post-procedural costs at €0 and found that the results of the economic evaluation remained similar (England: -428 €, France: -137 €, Germany: -33 €, Italy: -522 €, Scotland: -298 €, Spain: -854 €).
Discussion
LEADERS FREE was the first study to compare directly the clinical and economic outcomes of drug-coated and bare metal stents in patients at high risk of bleeding. Use of the drug-coated stent was associated with a better safety and reduced events rate at one year. This economic substudy provides information on the efficient stenting strategy in such patients. The average total one-year cost of drug-coated stent patients was consistently lower than the cost of bare metal stent patients, making the drug-coated intervention cost-saving. Overall, using cost weights from each of the six countries studied, we found that the drug-coated stent dominated the bare metal stent despite higher initial stent costs. This dominance of drug-coated stents was explained by the better results in safety and efficacy: hospital costs were reduced in all countries following fewer and shorter re-admissions, and lower costs. Between-country variations were mostly explained by differences in hospital costs; higher hospital costs were associated with a higher probability of drug-coated stents being dominant. Results were less striking for QALY than for clinical endpoint prevention due to the low sensitivity of the EQ-5D-5L to detect DCS cost-effective in patients at high bleeding risk quality-of-life improvements in coronary patients over a oneyear period. These results are in line with the NORSTENT study (with a five-year follow-up) that did not find significant differences in QALY while the rate of repeat revascularisation differed between groups 20 . The LEADERS FREE clinical trial found the drug-coated stent to be significantly superior in terms of safety (composite endpoint of death, MI and stent thrombosis of 9.4% vs. 12.9%, p<0.005) and efficacy (clinically indicated target lesion revascularisation of 5.1% vs. 9.8%, p<0.001), while the difference in hospital admissions for clinical events during that same period did not reach statistical significance. This is explained by the fact that several adverse events resulted in only one admission (e.g., stent thrombosis and PCI) that reduced the 10% difference in total clinical endpoints to a 3% difference in total re-admissions (Table 1, Table 2 ). Total costs were mainly driven by the costs of the initial procedure (hospital stay and stent cost); the cost of repeat admissions represented on average ¼ to ⅓ of total one-year costs. Thus, the difference in one-year costs was not proportional to the difference in clinical effects.
Cost-effectiveness ratios reported in the BASKET trial were €64,732 to prevent one major adverse cardiac event, and €40,467 per QALY gained, higher than our results where drug-coated stents were more effective and less costly. However, in the subgroup of high-risk patients, the efficiency was very much improved. Our findings are consistent with other studies that showed costeffectiveness ratios driven by stent prices and their number 1, 21, 22 . LEADERS FREE reported about the same number of stents per lesion as the BASKET trial 1 , while other trials had fewer stents per patient 23, 24 .
Economic evaluations of drug-eluting stents versus bare metal stents consistently showed that the former are more effective in reducing major adverse cardiac events (MACE) and also more costly. In the SIRIUS trial, the base-case analysis found an incremental cost-effectiveness ratio for sirolimus-eluting stenting at US $1,650 per repeat revascularisation avoided, a cost utility of US $27,540 per QALY gained, <US $50,000 per QALY in 63.2% and <US $100,000 per QALY in 87.1% of bootstrap simulations 24 . The initial costs of the drug-eluting stents can be offset in part when the follow-up period is long. A model-based economic evaluation of the Endeavor ® drug-eluting stent vs. the Driver ® bare metal stent (both Medtronic, Minneapolis, MN, USA) over a fouryear time period found an incremental cost-effectiveness ratio of £3,757/QALY 25 .
Our decision to pool results for efficacy and resource use but to separate resource costs per country is in line with findings that the factor most frequently cited as generating variability in economic results between locations was the unit costs associated with particular resources 26 .
Limitations
Repeat admissions were selected to be included in the cost analysis when they occurred at the same date as a cardiac event described as safety or efficacy endpoints in the trial data. We did not use the hospitals' discharge data principal diagnoses because: 1) the coding rules of principal diagnoses differ between countries, and 2) principal diagnoses are sometimes coded according to economic rather than clinical criteria. We used the same mark-up in stent price for all countries because the exact per-country prices were not disclosed by the manufacturers for confidentiality reasons.
Conclusions
Taking into account the country level differences in hospital costs, we found that using Biolimus A9 drug-coated stents in patients at high bleeding risk was cost-effective compared to bare metal stents.
Impact on daily practice
Our study showed that, in patients at high bleeding risk, DCS were probably (>50%) cost-saving in six different European countries, and were almost certainly (>98%) costeffective with a willingness to pay at €10,000 per clinical event avoided. These results are needed for the DCS price discussion in European countries.
